Quantcast

Posts related to ‘PRGS’

24/7 Wall St. Closing Bell (F, GM, TM, EMC, GD, GMCR, POT, TIVO, UNF, PRGS, STZ, MON, FDO, LCAV, REE, NFLX, APKT, LPHI)

Posted: January 4, 2012 at 4:04 pm

Markets opened lower today and stayed in negative territory until mid-afternoon. Car makers reported December sales throughout the day, with Ford Motor Co. (NYSE: F) and General Motors Co. (NYSE: ...
Read Full Story »

Mornings Movers (LCAV, LPHI, APKT, PRGS, TIVO)

Posted: January 4, 2012 at 10:57 am

There are several stocks trading more heavily than usual this morning, and also experiencing large gains or drops in share prices. These include LCA-Vision Inc. (NASDAQ: LCAV), Life Partners Holdings ...
Read Full Story »

24/7 Wall St. Closing Bell (AAPL, GGP, UA, PLD, AKAM, WSM, PRGS, OSH, AVEO, KIOR, ASM, AONE, ARL)

Posted: January 3, 2012 at 4:09 pm

US stock markets rallied on the first morning of trading in the new year. Index futures were up sharply and trading zoomed past the mark to rise more than 2%. ...
Read Full Story »

52-Week High Club (GOOG, JBL, PRGS)

Posted: December 22, 2009 at 4:07 pm

Google Inc. (NASDAQ: GOOG) rose close to 0.5% to a yearly high of $601.50, carried by the momentum of the market. Jabil Circuit Inc. (NYSE: JBL) rose over 14% to ...
Read Full Story »
Money_stack_pic

Top Analyst Upgrades & Downgrades (BKD, SNH, AMZN, AAUK, CENX, EBAY, PRGS)

Posted: December 19, 2008 at 7:27 am

These are some of the top pre-market analyst upgrades and downgrades we have seen from Wall Street this Friday morning with more than two hours until the market opens:Brookdale Senior ...
Read Full Story »

Progress Acquires IONA Technologies (PRGS, IONA)

Posted: June 25, 2008 at 8:35 am

Progress Software Corporation (NASDAQ: PRGS) and IONA Technologies plc (NASDAQ: IONA) are going to see active trading today.  Progress is acquiring IONA in a cash buyout of $162 million and ...
Read Full Story »

Pre-Market Stock News (June 19, 2007)

Posted: June 19, 2007 at 7:11 am

(ALTH) Allos Therapeutics trading down 20% after its Phase III study of Efaproxyn failed to meet primary endpoint of improvement in overall survival.(BAY) Bayer raised guidance on Schering integration.(BMY) Bristol-Myers: ...
Read Full Story »